Join our daily newsletter At The Bell to receive exclusive market insights
BlinkLab (ASX:BB1) has confirimed its involvement in a Monash Uni-based study examining its tech’s ability to diagnose autism and ADHD.
BlinkLab offers software that analyses a child’s eye movements informed by research suggesting those with autism and ADHD display unique eye behaviours not witnessed in people without those conditions.
Thus the company name.
BlinkLab now finds itself on a data-finding mission within the larger Monash MAGNET large cohort study which is trying to enrol 1,000 families with children diagnosed with either or both conditions. The uni’s Turner Institute is ultimately overseeing the program.
“Using BlinkLab Dx 1, we aim to complete comprehensive deep sensory phenotyping of subjects with only autism, only ADHD, or with both autism and ADHD from the large MAGNET cohort,” the company wrote on Wednesday.
“The project will help to unravel the complex symptoms of [both conditions.]”
BlinkLab – and heads at Turner and Monash – are trying to figure out if the company’s software can outperform other traditional diagnosis methods.
“Participation in the MAGNET study will enable BlinkLab to assess how its digital biomarkers, including the PPI measure, correlate with other validated behavioural, neurocognitive, neuroimaging and, potentially, genetic markers,” BB1 CEO Dr. Henk-Jan Boele said.
“Using these deep phenotyping and machine learning techniques, we expect to uncover novel, homogeneous data-driven clusters and subtypes of these diseases with significant future implications for better and more personalised autism and ADHD diagnosis and treatment.”
BB1 last traded at 31cps.
Join the discussion: See what HotCopper users are saying about BlinkLab and be part of the conversations that move the markets.
